Disease/Infection News

RSS

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

Dry eye strikes most often in spring

New ophthalmology research from the University of Miami shows that dry eye - the little understood culprit behind red, watery, gritty feeling eyes - strikes most often in spring, just as airborne allergens are surging.

24 Apr 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Common tapeworm drug effectively treats MRSA superbugs in lab

A new study provides evidence from lab experiments that a drug already used in people to fight tapeworms might also prove effective against strains of the superbug MRSA, which kills thousands of people a year in the United States.

24 Apr 2015

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

A group of leading scientists has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is spent on developing new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases.

24 Apr 2015

Copley Scientific to showcase new accessories at RDD Europe 2015

Cascade impaction is used for all inhaled product testing but is a manually intensive process. Copley Scientific’s sample preparation tools help to alleviate bottlenecks, ensure that testing is consistent, reproducible and controlled, and also reduce the risk of repetitive strain injury (RSI)...

24 Apr 2015

Mobidiag to present two new diagnostic platforms for infectious diseases at ECCMID 2015

Mobidiag Ltd, a Finnish molecular diagnostics company specializing in the development of innovative diagnostics solutions for infectious diseases, today announced the first public presentation of two new diagnostic platforms – Novodiag and Amplidiag Easy – at ECCMID 2015 in Copenhagen on April 25-28.

24 Apr 2015

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai.

24 Apr 2015

Recommended alcoholic hepatitis treatments fail to increase patients' survival

The main drugs used to treat alcoholic hepatitis are not effective at increasing patients' survival, a major study has found. In a trial of over 1,000 patients, prednisolone and pentoxifylline, treatments recommended in international guidelines, did not achieve a statistically significant reduction in mortality after 28 days, 90 days or a year.

24 Apr 2015

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company developing novel antioxidant molecules targeting mitochondria, today announced that it has achieved significant positive results in its U.S. Phase II clinical trial of SkQ1 compound in patients with moderate to severe dry eye syndrome.

24 Apr 2015

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

24 Apr 2015

Twins pilot study shows genes may make some people more attractive to mosquitoes

The likelihood of being bitten by mosquitoes could be down to our genes, according to a study carried out on twins. Research from the London School of Hygiene & Tropical Medicine found, for the first time, an underlying genetic component to how attractive we are to mosquitoes and this is likely to be caused by genetic control of our body odour.

24 Apr 2015

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO is calling on the global health community to urgently address significant gaps in the prevention, diagnosis and treatment of malaria. Despite dramatic declines in malaria cases and deaths since 2000, more than half a million lives are still lost to this preventable disease each year.

23 Apr 2015

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.

23 Apr 2015

Study highlights need to increase current levels of interventions to reduce HBV transmission

Results revealed today at The International Liver Congress 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible.

23 Apr 2015

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.

23 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.

23 Apr 2015

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Many countries in the World Health Organization European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver Congress 2015 has shown the devastating impact the infection has on their daily lives.

23 Apr 2015

Disease/Infection News

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Dry eye strikes most often in spring

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Common tapeworm drug effectively treats MRSA superbugs in lab

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

Copley Scientific to showcase new accessories at RDD Europe 2015

Mobidiag to present two new diagnostic platforms for infectious diseases at ECCMID 2015

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Recommended alcoholic hepatitis treatments fail to increase patients' survival

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Twins pilot study shows genes may make some people more attractive to mosquitoes

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Study highlights need to increase current levels of interventions to reduce HBV transmission

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News